Virta Health Surpasses $160M in Annualized Revenue as a Leader in Reversing Metabolic Disease

80% YoY growth driven by surging demand for company’s metabolic health solutions 

September 22, 2025 – DENVER, CO – Virta Health today announced it has surpassed $160 million in annualized revenue, marking a major milestone in its mission to reverse metabolic disease through a nutrition-first approach. With more than 80% year-over-year revenue growth, significant rise in membership, and improving profitability, Virta is one of digital health’s fastest-scaling companies, uniquely positioned to address the root cause of metabolic disease and offer sustainable alternatives to GLP-1 medications.

Virta’s momentum reflects surging demand for sustainable weight loss and diabetes reversal that goes beyond long-term reliance on GLP-1s. The company covers more than 12 million U.S. lives and serves about 550 employers, health plans, and federal and state government partners.

“We’re still in the early innings of solving the metabolic health crisis,” said Sami Inkinen, co-founder and CEO of Virta Health. “But we’ve proven that it’s possible to sustainably reverse diabetes and obesity at scale, and do it without lifetime medication. That’s what makes our model so powerful: better outcomes, lower costs, and a path to true health transformation, not just symptom management.”

New Data Reinforces Virta's Nutrition-First Model as a Sustainable Alternative to GLP-1s

As demand rises for cost-effective, long-term solutions beyond GLP-1s, new data shows Virta's nutrition-first approach delivers weight loss outcomes on par with these medications, while lowing costs and reducing reliance on the drugs.

More than 75% of Virta’s weight loss members are not on GLP-1s, with previously reported one year weight loss outcomes reaching 13% without the use of these medications. Even among those considering or taking GLP-1s, interest in drug-free options is strong: nearly 70% chose a nutrition-first approach, and only 20% of current users said they want to remain on the drugs long term.

For members who do use GLP-1s, Virta provides continuous, provider-led care designed to optimize outcomes, manage side effects, and support lifestyle change. For members who choose to taper off, Virta uniquely sustains weight loss through nutrition, an approach that also drives measurable impact for employers and health plans. One Fortune 100 client cut GLP-1 growth by 49% in just six months by pairing optimized prescribing with Virta’s nutrition-first alternative, bending the cost curve while improving outcomes.

‍

A Model Built for Scale, Sustainability, and Predictability

Virta’s rapid growth is powered by a care model designed to meet rising demand while delivering results that matter. The company offers industry-first guarantees to help organizations manage risk and improve predictability:

• A 0% GLP-1 utilization trend, eliminating unexpected drug cost inflation
• Guaranteed weight loss, aligning outcomes with value
• A 1:1 ROI guarantee, underscoring Virta’s ability to drive savings by delivering rapid and long lasting clinical outcomes

With GLP-1 spend projected to exceed $100 billion globally by 2030, Virta’s care model is purpose-built to help employers and health plans rein in costs without compromising outcomes.

‍